These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
170 related articles for article (PubMed ID: 24888356)
1. Incorporating external evidence in trial-based cost-effectiveness analyses: the use of resampling methods. Sadatsafavi M; Marra C; Aaron S; Bryan S Trials; 2014 Jun; 15():201. PubMed ID: 24888356 [TBL] [Abstract][Full Text] [Related]
2. Two-level resampling as a novel method for the calculation of the expected value of sample information in economic trials. Sadatsafavi M; Marra C; Bryan S Health Econ; 2013 Jul; 22(7):877-82. PubMed ID: 22933363 [TBL] [Abstract][Full Text] [Related]
3. Extrapolation of Survival Curves from Cancer Trials Using External Information. Guyot P; Ades AE; Beasley M; Lueza B; Pignon JP; Welton NJ Med Decis Making; 2017 May; 37(4):353-366. PubMed ID: 27681990 [TBL] [Abstract][Full Text] [Related]
4. Survival time outcomes in randomized, controlled trials and meta-analyses: the parallel universes of efficacy and cost-effectiveness. Guyot P; Welton NJ; Ouwens MJ; Ades AE Value Health; 2011; 14(5):640-6. PubMed ID: 21839400 [TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness analysis using data from multinational trials: the use of bivariate hierarchical modeling. Manca A; Lambert PC; Sculpher M; Rice N Med Decis Making; 2007; 27(4):471-90. PubMed ID: 17641141 [TBL] [Abstract][Full Text] [Related]
6. Analysis of cost data in randomized trials: an application of the non-parametric bootstrap. Barber JA; Thompson SG Stat Med; 2000 Dec; 19(23):3219-36. PubMed ID: 11113956 [TBL] [Abstract][Full Text] [Related]
8. Non-parametric methods for cost-effectiveness analysis: the central limit theorem and the bootstrap compared. Nixon RM; Wonderling D; Grieve RD Health Econ; 2010 Mar; 19(3):316-33. PubMed ID: 19378353 [TBL] [Abstract][Full Text] [Related]
9. Assessing and comparing costs: how robust are the bootstrap and methods based on asymptotic normality? O'Hagan A; Stevens JW Health Econ; 2003 Jan; 12(1):33-49. PubMed ID: 12483759 [TBL] [Abstract][Full Text] [Related]
10. Building a Bayesian bridge from evidence to guidelines. Goodman SN Arch Intern Med; 2009 Aug; 169(15):1436-7. PubMed ID: 19667309 [No Abstract] [Full Text] [Related]
11. Choice of statistical model for cost-effectiveness analysis and covariate adjustment: empirical application of prominent models and assessment of their results. Mantopoulos T; Mitchell PM; Welton NJ; McManus R; Andronis L Eur J Health Econ; 2016 Nov; 17(8):927-938. PubMed ID: 26445961 [TBL] [Abstract][Full Text] [Related]
12. A framework for cost-effectiveness analysis from clinical trial data. O'Hagan A; Stevens JW Health Econ; 2001 Jun; 10(4):303-15. PubMed ID: 11400253 [TBL] [Abstract][Full Text] [Related]
13. Cluster randomized trials: another problem for cost-effectiveness ratios. Flynn TN; Peters TJ Int J Technol Assess Health Care; 2005; 21(3):403-9. PubMed ID: 16110722 [TBL] [Abstract][Full Text] [Related]
14. Incorporating considerations of cost-effectiveness, affordability, and resource implications in guideline development: article 6 in Integrating and coordinating efforts in COPD guideline development. An official ATS/ERS workshop report. Hill SR; Olson LG; Falck-Ytter Y; Cruz AA; Atkins D; Baumann M; Jaeschke R; Woitalla T; Schünemann HJ; Proc Am Thorac Soc; 2012 Dec; 9(5):251-5. PubMed ID: 23256167 [TBL] [Abstract][Full Text] [Related]
15. Bayesian hierarchical models for cost-effectiveness analyses that use data from cluster randomized trials. Grieve R; Nixon R; Thompson SG Med Decis Making; 2010; 30(2):163-75. PubMed ID: 19675321 [TBL] [Abstract][Full Text] [Related]